This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Novartis Vaccines & Diagnostics, Gmbh. Active years: 2012-2014.
Company Filing History:
Years Active: 2012-2014
Title: The Innovations of Deborah Hurst
Introduction
Deborah Hurst is a notable inventor based in Piedmont, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 2 patents, her work focuses on innovative methods for treating diseases mediated by CD40 signaling.
Latest Patents
Hurst's latest patents include the development of antagonist anti-CD40 monoclonal antibodies and methods for their use. These compositions and methods provide therapeutic approaches for treating diseases that involve the stimulation of CD40 signaling on CD40-expressing cells. The methods involve administering a therapeutically effective amount of an antagonist anti-CD40 antibody or its antigen-binding fragment to patients in need. Importantly, the antagonist anti-CD40 antibody is designed to be free of significant agonist activity while exhibiting antagonist activity when binding to a CD40 antigen on human CD40-expressing cells. This antagonist activity is beneficial as it inhibits the proliferation and differentiation of human CD40-expressing cells, such as B cells.
Career Highlights
Deborah Hurst is currently employed at Novartis Vaccines & Diagnostics GmbH, where she continues to advance her research and innovations in the field. Her work has been instrumental in developing therapies that target critical pathways in immune response.
Collaborations
Hurst collaborates with talented colleagues, including Li Long and Asha Yabannavar, who contribute to her research efforts and the advancement of their shared goals in biotechnology.
Conclusion
Deborah Hurst's contributions to the field of biotechnology through her innovative patents and collaborations highlight her role as a leading inventor in therapeutic antibody development. Her work continues to pave the way for new treatments that can significantly impact patient care.